

CORRECTIONS

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

There is an error in this Research paper by Karagiannis and colleagues (*BMJ* 2012;344:e1369, doi:10.1136/bmj.e1369) and in our previously published correction (*BMJ* 2012;345:e4959). In the final paragraph of the section "Glycaemic efficacy," the risk ratio in favour of GLP-1 agonists should have been 1.82, 95% confidence interval 1.50 to 2.21; $I^2=0\%$ [not "1.33, 1.09

to 1.63; $I^2=26\%$ " as published in the original paper, or "1.82, 95% confidence interval 1.50 to 2.21; $I^2=26\%$ " as published in the previous correction].

Cite this as: *BMJ* 2012;345:e5129

© BMJ Publishing Group Ltd 2012